Global Targeted Drug EGFR RTK Inhibitors for NSCLC Market Growth (Status and Outlook) 2025-2031
Description
According to this study, the global Targeted Drug EGFR RTK Inhibitors for NSCLC market size will reach US$ million by 2031.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
LPI (LP Information)' newest research report, the “Targeted Drug EGFR RTK Inhibitors for NSCLC Industry Forecast” looks at past sales and reviews total world Targeted Drug EGFR RTK Inhibitors for NSCLC sales in 2024, providing a comprehensive analysis by region and market sector of projected Targeted Drug EGFR RTK Inhibitors for NSCLC sales for 2025 through 2031. With Targeted Drug EGFR RTK Inhibitors for NSCLC sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Targeted Drug EGFR RTK Inhibitors for NSCLC industry.
This Insight Report provides a comprehensive analysis of the global Targeted Drug EGFR RTK Inhibitors for NSCLC landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on Targeted Drug EGFR RTK Inhibitors for NSCLC portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Targeted Drug EGFR RTK Inhibitors for NSCLC market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Targeted Drug EGFR RTK Inhibitors for NSCLC and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Targeted Drug EGFR RTK Inhibitors for NSCLC.
This report presents a comprehensive overview, market shares, and growth opportunities of Targeted Drug EGFR RTK Inhibitors for NSCLC market by product type, application, key players and key regions and countries.
Segmentation by Type:
Icotinib
Gefitinib
Erlotinib
Afatinib
Osimertinib
Brigatinib
Others
Segmentation by Application:
Squamous Cell Carcinoma of NSCLC
Adenocarcinoma of NSCLC
Large Cell Carcinoma of NSCLC
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Beta Pharma
AstraZeneca
Natco Pharma
Qilu Pharmaceutical
Genentech (Roche Group)
Mylan
Teva
OSI Pharmaceuticals
Glenmark Pharmaceuticals
Beacon Pharmaceuticals
Boehringer Ingelheim
Pfizer
ARIAD Pharmaceuticals (Takeda)
Genvio Pharma Limited
Drug International Limted
Everest Pharmaceuticals
Incepta Pharmaceuticals Limited
Cipla Pharma
Dr Reddy's Laboratories
Zydus Cadila
Hetero Drugs
Intas Pharmaceuticals
Alkem Laboratories
RPG Life Sciences
Fresenius Kabi India
Please note: The report will take approximately 2 business days to prepare and deliver.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
LPI (LP Information)' newest research report, the “Targeted Drug EGFR RTK Inhibitors for NSCLC Industry Forecast” looks at past sales and reviews total world Targeted Drug EGFR RTK Inhibitors for NSCLC sales in 2024, providing a comprehensive analysis by region and market sector of projected Targeted Drug EGFR RTK Inhibitors for NSCLC sales for 2025 through 2031. With Targeted Drug EGFR RTK Inhibitors for NSCLC sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Targeted Drug EGFR RTK Inhibitors for NSCLC industry.
This Insight Report provides a comprehensive analysis of the global Targeted Drug EGFR RTK Inhibitors for NSCLC landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on Targeted Drug EGFR RTK Inhibitors for NSCLC portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Targeted Drug EGFR RTK Inhibitors for NSCLC market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Targeted Drug EGFR RTK Inhibitors for NSCLC and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Targeted Drug EGFR RTK Inhibitors for NSCLC.
This report presents a comprehensive overview, market shares, and growth opportunities of Targeted Drug EGFR RTK Inhibitors for NSCLC market by product type, application, key players and key regions and countries.
Segmentation by Type:
Icotinib
Gefitinib
Erlotinib
Afatinib
Osimertinib
Brigatinib
Others
Segmentation by Application:
Squamous Cell Carcinoma of NSCLC
Adenocarcinoma of NSCLC
Large Cell Carcinoma of NSCLC
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Beta Pharma
AstraZeneca
Natco Pharma
Qilu Pharmaceutical
Genentech (Roche Group)
Mylan
Teva
OSI Pharmaceuticals
Glenmark Pharmaceuticals
Beacon Pharmaceuticals
Boehringer Ingelheim
Pfizer
ARIAD Pharmaceuticals (Takeda)
Genvio Pharma Limited
Drug International Limted
Everest Pharmaceuticals
Incepta Pharmaceuticals Limited
Cipla Pharma
Dr Reddy's Laboratories
Zydus Cadila
Hetero Drugs
Intas Pharmaceuticals
Alkem Laboratories
RPG Life Sciences
Fresenius Kabi India
Please note: The report will take approximately 2 business days to prepare and deliver.
Table of Contents
151 Pages
- *This is a tentative TOC and the final deliverable is subject to change.*
- 1 Scope of the Report
- 2 Executive Summary
- 3 Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size by Player
- 4 Targeted Drug EGFR RTK Inhibitors for NSCLC by Region
- 5 Americas
- 6 APAC
- 7 Europe
- 8 Middle East & Africa
- 9 Market Drivers, Challenges and Trends
- 10 Global Targeted Drug EGFR RTK Inhibitors for NSCLC Market Forecast
- 11 Key Players Analysis
- 12 Research Findings and Conclusion
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
